Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is two-fold. (1) We will determine if in mid- to late pubertal girls without hyperandrogenism (HA), progesterone (P4) acutely reduces waking luteinizing hormone (LH) frequency to a greater extent than sleep-associated LH frequency. (2) We will determine if in mid- to late pubertal girls with HA, P4 will acutely suppress waking LH frequency to a lesser degree than it does in girls without HA.


Clinical Trial Description

This is a randomized, placebo-controlled, double-blinded crossover study to test the following hypotheses: (1) In normal mid- to late pubertal girls without hyperandrogenism (HA), progesterone acutely suppresses waking LH pulse frequency more than sleep-associated LH pulse frequency; and (2) compared to normal mid- to late pubertal girls without HA, acute progesterone suppression of waking LH pulse frequency is impaired in mid- to late pubertal girls with HA. Studies will be performed in mid- to late pubertal girls (at least Tanner breast stage 3 but no more than 2 years postmenarcheal). Subjects will complete two 18-hour Clinical Research Unit (CRU) admissions in separate menstrual cycles. Immediately before and during the first CRU admission, either oral micronized progesterone (0.8 mg/kg/dose) or placebo (randomized) will be given at 0700, 1500, 2300, and 0700 h. During the CRU admission, blood will be obtained every 10 minutes through an indwelling iv catheter from 1800 to 1200 h. This will allow full characterization of pulsatile LH secretion in addition to other hormone measurements. A second CRU admission (performed at least 2 months later given blood withdrawal limits) will be identical to the first except that placebo will exchanged for progesterone or vice versa (treatment crossover). The primary endpoint is LH pulse frequency while awake. (LH pulse frequency while asleep is an important secondary endpoint.) Results in pubertal girls without HA were recently published (Kim et al, J Clin Endocrinol Metab 2018;103:1112-1121). Data from girls with HA will be compared to recently-published results in girls without HA. Mean LH pulse frequency while awake will be analyzed via a hierarchical linear mixed model (HLMM). HA status (HA vs. non-HA), sleep status (wake vs. sleep), and treatment (progesterone vs. placebo) will represent fixed-effects, along with all associated interactions. Random effects will be used to account for hierarchical variance-covariance structure of the crossover study design. With regard to hypothesis testing, the association between HA status and wake LH pulse frequency will be evaluated via linear contrasts of HLMM least squares pulse frequency means. The differential impact of exogenous progesterone on wake LH pulse frequency in pubertal girls with and without HA (primary analysis) will be evaluated via the same testing method. Using published and preliminary data, we determined that, if 16 pubertal girls with HA complete both admissions, we should have at least an 80% chance of detecting a 0.2 pulse/hour differential effect of P4 on wake LH pulse frequency between the HA and the non-HA groups with a two-sided false positive rejection rate of no more than 0.05. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00929006
Study type Interventional
Source University of Virginia
Contact Melissa Gilrain
Phone 434-243-6911
Email pcos@virginia.edu
Status Recruiting
Phase Early Phase 1
Start date June 2008
Completion date December 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05112029 - Metabolic Profile and Adipokine Levels in Young Hyperandrogenemic Females
Terminated NCT01428193 - Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone N/A
Enrolling by invitation NCT04485403 - The Effect of Ibuprofen on Women With PCOS. Phase 2
Active, not recruiting NCT00930007 - Sleep-wake Changes of Luteinizing Hormone Frequency in Pubertal Girls With and Without High Testosterone
Completed NCT03252223 - Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS Phase 4
Terminated NCT02523898 - Metformine and CC Compared With Placebo and CC for Induction Ovulation in PCOS Patients With Insulin Resistant Phase 2
Recruiting NCT04723862 - Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism? Early Phase 1
Suspended NCT02611128 - Urinary DENND1A.V2 as a Predictor of Pubertal Hyperandrogenemia
Recruiting NCT04453306 - Treatment of Obesity With Topiramate in Patients With Polycystic Ovary Syndrome Phase 4
Recruiting NCT04979377 - Prevalence of Hyperandrogenism in Type 1 Diabetes
Recruiting NCT05926115 - Phenotype and Epidemiology of the Polycystic Ovary Syndrome (PCOS) in Colombia (PEP - Colombia) Study.
Active, not recruiting NCT01569425 - Meal Timing on Glucose Metabolism and Hyperandrogenism in Lean Women With Polycystic Ovary Syndrome N/A
Recruiting NCT01428089 - Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone Phase 1
Active, not recruiting NCT01421810 - Ovarian Contribution to Androgen Production in Adolescent Girls N/A
Completed NCT01313455 - Adrenal Hyperplasia Among Young People With PCOS
Completed NCT03188640 - Bariatric Surgery, Hormones, and Quality of Life N/A
Not yet recruiting NCT02402413 - Ultrasound Three-dimensional Characterization of Ovarian Morphology in Women With Polycystic Ovary Syndrome (PCOS) N/A
Completed NCT02651636 - Combined Therapy With Myo-inositol and Alpha-Lipoic Acid in PCOS Women N/A
Not yet recruiting NCT00665171 - Whole Genome Analysis for the Detection of Key Genes in the Polycystic Ovary Syndrome N/A
Recruiting NCT03757923 - Comparison of Metformin and Pioglitazone in Regulating Menstrual Irregularities and Hyperandrogenism Phase 1/Phase 2